Corcept Therapeutics (NASDAQ: CORT) announced the commencement of its fourth Phase 3 trial, Study 14, evaluating CORLUX for the treatment of the psychotic features of psychotic depression. This trial is a randomized, double-blinded, placebo-controlled study which will enroll up to 450 patients at approximately 25 sites in the United States. In connection with this study Corcept also announced the signing of an agreement with MedAvante, Inc.
Popularity: unranked [?]
Related posts:
- Corcept Therapeutics Announces Negative Results From The Second Of Three Phase 3 Studies Evaluating CORLUX(R) For Treating Psychotic Features
- Corcept Therapeutics Announces Negative Results From The First Of Three Phase 3 Studies Evaluating CORLUX(R) For Psychotic Major Depression
- Corcept Therapeutics Completes Enrollment In Second Phase 3 Study For Treating Psychotic Major Depression
- Corcept Therapeutics Completes Enrollment In Third Phase 3 Study For Treating Psychotic Major Depression
- Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression
Comments
No Responses to “Corcept Therapeutics Announces Commencement Of Next Phase 3 Study With CORLUX(R) For The Treatment Of Psychotic Depression”